Antibody

The US Food and Drug Administration (FDA) has granted clearance to Transcenta to proceed with its TranStar 301 global Phase III pivotal trial of Osemitamab (TST001) for gastric cancer. The trial will investigate the drug in combination with Nivolumab and chemotherapy as a first-line treatment in patients with HER2-negative, CLDN18.2 expressing locally advanced or metastatic […]

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, has announced data from a pre-defined interim analysis related to the lung cohort of the Phase II basket trial (IOB-022/KN-D38) with IO102-IO103 in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy as first-line therapy. These data were presented at […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Diana Spencer has chosen news stories this week which all discuss pre-clinical research studies that could have a huge impact on our therapeutic […]

News round-up for 14-18 August by DDW Digital Content Editor Diana Spencer. My chosen news stories this week all discuss pre-clinical research studies that could have a huge impact on our therapeutic approach to several hard-to-treat diseases, helping to overcome drug-resistance and make treatments more targeted in the future. Next-generation antivirals could target virus membranes […]

Researchers have shown that a novel antibody has greater activity and potentially fewer side effects than existing biological therapies for conditions such as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD). The antibody, called Ab-IPL-IL-17, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during […]

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The Phase I clinical trial, sponsored and managed by Cancer Research UK’s Centre for Drug Development, tested whether an IgE antibody could be used to treat cancer. […]

The Summer 2023 issue of Drug Discovery World Magazine is out now and includes an exclusive guide on Therapeutic Antibodies.  Featuring a Therapeutic Spotlight on Immuno-oncology, the magazine is available to download free here and read for free on the DDW App.  You can also request to receive a copy of the printed magazine here.  Key features of the Summer issue include a […]

IgGenix has made advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies. The company’s research data was presented during the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress, in Hamburg, Germany. The data shows that nearly all peanut-specific IgE antibodies discovered from peanut-allergic individuals were high affinity, with many exhibiting double-digit […]

The US Food and Drug Administration (FDA) has given approval to Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection with Enhanze for subcutaneous (SC) use for the treatment of generalised myasthenia gravis (gMG). The treatment is approved in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. Vyvgart Hytrulo is a subcutaneous product combination of efgartigimod […]

Janssen has presented new data from across its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Talquetamab Talquetamab is an investigational GPRC5D-directed bispecific antibody currently in clinical development. Updated results from the Phase II MonumenTAL-1 study show that with a median of 13-19 months of follow-up, talquetamab continues to […]

Eisai has submitted a marketing authorisation application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody to the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. The MAA is for the treatment of early Alzheimer’s disease (AD) (mild cognitive impairment due to AD and mild AD dementia) with confirmed amyloid pathology in […]

Patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% overall response rate. This is according to results of a Phase I/II clinical trial presented at the AACR Annual Meeting 2023 in Florida. REGN5459 binds to BCMA on […]

Merck has bought the exclusive worldwide rights to develop, manufacture and commercialise anti PD-L1 antibody Bavencio (avelumab) from Pfizer. Merck will take full control of the global commercialisation of Bavencio through its affiliate Ares Trading. The transaction has also ended a long-term collaboration between Merck and Pfizer. The current profit share will be replaced by […]

San Francisco-based biotechnology company Infinimmune is emerging from stealth with its $12 million seed financing. The company is co-founded by former team leaders and multi-disciplinary tool builders from 10x Genomics. Taking a human-first approach, Infinimmune is leveraging single-cell technology to create truly human antibody-based therapeutics directly derived from the human immune system. DDW’s Megan Thomas […]

This article is sponsored by Bethyl Laboratories. For over 50 years, Bethyl Laboratories (now a Fortis Life Sciences brand) has been dedicated to improving lives by supporting scientific discovery through qualified antibody products and custom services. We are vertically-integrated from immunisation through manufacturing and validation. All of our antibodies are highly validated using six pillars […]

Increasing collaborations and partnerships between market players are expected to contribute to significant growth in the antibodies market between 2022 and 2030, ResearchAndMarkets.com predicts.   In one example from March 2022, Sanofi and Seagen announced an exclusive collaboration agreement to design, develop, and market antibody-drug conjugates (ADCs) for up to three cancer targets.  The collaboration will […]